Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "flu-vaccine"

12 News Found

Croda secures financial support from UK Government for expansion of lipid systems manufacturing facility
News | April 04, 2022

Croda secures financial support from UK Government for expansion of lipid systems manufacturing facility

The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines

Novavax initiates Phase 1/2 trials combining vaccine for Covid-19 and seasonal influenza
Biotech | September 09, 2021

Novavax initiates Phase 1/2 trials combining vaccine for Covid-19 and seasonal influenza

First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety

Latest Stories

GSK names Luke Miels as next CEO

BMS launches BMS patient connect, expands direct-to-patient access with Sotyktu

Gleneagles Hospital Mumbai and Medtronic host conclave on hub & spoke model and AI in healthcare

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging